close up of lab technician in full protective clothing using microscope

Roquefort Therapeutics

Focused on developing first in class medicines in the high value and high growth immuno-oncology market prior to partnering or selling to big pharma

Find out more

Roquefort Therapeutics plc is a material biotech company focused on next generation medicines for hard to treat cancers

Roquefort Therapeutic PLC Logo


2020 Company Founded
5 Pre - Clinical Programs
2021 IPO London Main Market

Regulatory News

Regulatory News

20.06.2024

Appointment of Broker

Read more: Appointment of Broker
04.06.2024

Notice of Annual General Meeting

Read more: Notice of Annual General Meeting
23.05.2024

Issue of Convertible Loan Notes & Board Changes

Read more: Issue of Convertible Loan Notes & Board Changes
macro photo of droplets in oil with a blue background

Our Portfolio

Our portfolio consists of five novel patent-protected pre-clinical anti-cancer medicines.
The highly complementary portfolio of best-in-class medicines is focused on the cancers that remain resistant to existing therapies and creates significant upside potential in high value and high growth immuno-oncology market.

 

blue gloved hands holding laboratory tray

Leadership

Expert leadership team with proven track record in drug development, regulatory approvals and biotech transactions.
The team includes Nobel Laureate, Professor Sir Martin Evans and experienced biotechnology CEO, Ajan Reginald.

 

close up of lab technician examining slide under microscope wearing a blue rubber glove

State of the art facility

Access to state of the art laboratory located in Stratford-upon-Avon that includes a clean room, laminar flow cabinets and cryopreservation infrastructure required for pre-clinical development of innovative new medicines, particularly cell and gene therapies.

 

lab technician using microscope dressed in white lab coat

Partnering

Network of partnerships with leading academic cancer research centres which complements our own world-class in-house expertise and laboratory infrastructure and enables us to implement a broader and more effective development strategy.
This distributed R&D model is highly scalable and cost effective.